Guy Martin
ReporterThe Pharma Letter
Guy Martin has been a journalist since 2008.
He writes about all areas of pharma and biotech, and related business news.
He has a special interest in emerging technologies leading to the development of personalized medicines, along with the changes this will bring to the pharmaceutical industry and beyond.
Today's issue
Refine Search
Latest from Guy Martin
Pharmaceutical
Love it or loathe it, the Institute for Clinical and Economic Review (ICER) is not about to go away. 25 January 2019
Pharmaceutical
Pipelines are the future of pharma, providing an indication of which patients, companies and shareholders will benefit from the next generation of cures and treatments. 24 January 2019
Biotechnology
Members of the deals team at Arix Bioscience, a London-listed venture capital (VC) firm specializing in biotech, are so well-connected that they will never lack for new innovations to invest in. 4 January 2019
Biosimilars
Given that copycat biologics are a relatively new part of the healthcare landscape, especially in the USA, the blueprint on how to become a successful biosimilars company is yet to established. 14 December 2018
Pharmaceutical
When Per Falk, Ferring’s chief science officer, assumes the additional responsibility of becoming president of the executive committee on January 1 next year, he will be the envy of many big pharma leaders. 5 November 2018
Pharmaceutical
For the era of personalized therapies to truly arrive, industry observers often express the view that pharma will have to improve its understanding not just of biology and medicines, but also of certain new technologies that are likely to determine companies’ future way of working. 30 October 2018
Pharmaceutical
Russia’s arrival as a major player in the digitalization of healthcare was abundantly clear at a Moscow event held to celebrate and stimulate advances in the sector. 25 October 2018
Pharmaceutical
Previous scandals and improvements in standards and transparency mean that the conversations and exchanges of information that take place between pharmaceutical companies and healthcare practitioners (HCPs) are now closely regulated in many countries. 12 October 2018
Biotechnology
When Novartis’ Kymriah (tisagenlecleucel) was made available to a small group of young patients in an agreement with NHS England less than a month ago, the decision came just 10 days after the drug was approved in Europe. 23 September 2018
Pharmaceutical
“The Russian pharma market is like a huge ocean. If you know who lives in the ocean and what sort of currents the ocean has, then it is all simple and understandable.” 10 August 2018
Pharmaceutical
“The innovation and transformative potential that this pipeline holds really give us a lot of confidence that we are going to emerge as a strong player in the oncology space.” 3 August 2018
Pharmaceutical
The growth of privately-held Swiss drugmaker Ferring Pharmaceuticals in the US market has been nothing short of remarkable. 14 July 2018
Biotechnology
Since it first received US approval for thyroid cancer in February 2015, excitement around Eisai’s Lenvima (lenvatinib mesylate) as one of the hottest properties in oncology has steadily been growing. 4 July 2018
Pharmaceutical
Pharma companies sometimes need to be aware of advances in wearable technology that threaten to take market share away from their medicines, but such devices can also work well when used in conjunction with drugs. 2 July 2018
Pharmaceutical
Jesus Gomez-Navarro, vice president, head of oncology clinical research and development at Takeda Oncology, talks of three elements to the unit’s R&D strategy and three highlights in its pipeline when talking to The Pharma Letter about the most exciting abstracts being presented on the company’s cancer candidates at two major conferences this month. 20 June 2018
Biotechnology
Experts from the International Society for Cell and Gene Therapy (ISCT) told The Pharma Letter last month that the last 12 months had been the most important yet for advances in their field. 10 June 2018
Pharmaceutical
Belén Garijo has been the chief executive of the Healthcare business of German life sciences group Merck KGaA since 2015. Speaking to The Pharma Letter, she discusses her company’s quest to overcome the chronic disease ... 17 May 2018
Pharmaceutical
The progress achieved in treating huge swathes of the world’s HIV-infected population in the last 20 to 30 years might give the impression of a therapy area where few challenges remain. 8 May 2018
Biotechnology
A newcomer on the biologics scene expressing a vision to become a global player is nothing new, but it is a bold ambition when coming from CinnaGen, an Iranian biosimilars company that is only just starting its journey in the world’s major pharma markets. 30 April 2018
Biosimilars
It was no fluke when Celltrion Healthcare became the first drug developer to win approval for a biosimilar monoclonal antibody (mAb) from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) with its copy of Remicade (infliximab). 13 April 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze